Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HRS-4139 in Psoriasis vulgaris: NCT07802964 Clinical Landscape Report 2026
11 September 2026
NCT07802964 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Pancreatic adenocarcinoma: NCT07808567 Clinical Landscape Report 2026
11 September 2026
NCT07808567 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[18F]-D2-deprenyl in Multiple Sclerosis: NCT07805473 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_13_1a4cebe3b5.jpg)
9 min read
[18F]-D2-deprenyl in Multiple Sclerosis: NCT07805473 Clinical Landscape Report 2026
11 September 2026
NCT07805473 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lidocaine in Analgesia: NCT07809425 Clinical Landscape Report 2026
11 September 2026
NCT07809425 clinical landscape for Analgesia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tumor-Targeted Drug Conjugate(TwoStep) in Ovarian Cancer: NCT07814248 Clinical Landscape Report 2026
11 September 2026
NCT07814248 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CS1-targeted autologous CAR-T cells (Hematology Hospital of Chinese Academy of Medical Sciences) in Relapse multiple myeloma: NCT07809594 Clinical Landscape Report 2026
11 September 2026
NCT07809594 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TUB-040 in Metastatic Non-Squamous Non-Small Cell Lung Carcinoma: NCT07806773 Clinical Landscape Report 2026
11 September 2026
NCT07806773 clinical landscape for Metastatic Non-Squamous Non-Small Cell Lung Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
C-CAR168 in Neuromyelitis Optica: NCT07676266 Clinical Landscape Report 2026
11 September 2026
NCT07676266 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07704892 Clinical Landscape Report 2026
11 September 2026
NCT07704892 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Navlimetostat in Mesothelioma, Malignant: NCT07602946 Clinical Landscape Report 2026
11 September 2026
NCT07602946 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Crizotinib in Uveal Melanoma: NCT07804186 Clinical Landscape Report 2026
11 September 2026
NCT07804186 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rentosertib in Idiopathic Pulmonary Fibrosis: NCT07687459 Clinical Landscape Report 2026
11 September 2026
NCT07687459 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.